Adagene Inc. ADAG · Stock Open Adagene Inc. in new tab
Adagene Inc. Analysis (ADAG)
Is Adagene Inc. a good investment? Adagene Inc. (ADAG) is currently trading at 3.98 USD. Market analysts have a consensus price target of 9.40 USD. This suggests a potential upside from current levels.
Earnings Schedule: Adagene Inc. is expected to release its next earnings report on Sept. 2, 2026. The market consensus estimate for Forward EPS is -0.52.
Investor FAQ
Does Adagene Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Adagene Inc.?
Adagene Inc. is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Sept. 2, 2026. The company currently has a trailing EPS of -0.37.
Company Profile
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. Adagene Inc. was incorporated in 2011 and is headquartered in Suzhou, China.
Community Discussion